Editas Medicine, Inc.

LSE:0IFK Stock Report

Market Cap: US$94.1m

Editas Medicine Management

Management criteria checks 2/4

Editas Medicine's CEO is Gilmore O’Neill, appointed in Jun 2022, has a tenure of 2.58 years. total yearly compensation is $2.39M, comprised of 26.8% salary and 73.2% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $125.35K. The average tenure of the management team and the board of directors is 1.8 years and 5.9 years respectively.

Key information

Gilmore O’Neill

Chief executive officer

US$2.4m

Total compensation

CEO salary percentage26.8%
CEO tenure2.6yrs
CEO ownership0.1%
Management average tenure1.8yrs
Board average tenure5.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Gilmore O’Neill's remuneration changed compared to Editas Medicine's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$211m

Jun 30 2024n/an/a

-US$193m

Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$2mUS$641k

-US$153m

Sep 30 2023n/an/a

-US$195m

Jun 30 2023n/an/a

-US$206m

Mar 31 2023n/an/a

-US$219m

Dec 31 2022US$9mUS$356k

-US$220m

Compensation vs Market: Gilmore's total compensation ($USD2.39M) is above average for companies of similar size in the UK market ($USD343.93K).

Compensation vs Earnings: Gilmore's compensation has been consistent with company performance over the past year.

CEO

Gilmore O’Neill (60 yo)

2.6yrs

Tenure

US$2,392,309

Compensation

Dr. Gilmore O’Neill, M.B., M. M.SC., serves as Member of Scientific Advisory Board of AavantiBio, Inc. since February 2022. He is President & CEO of Editas Medicine, Inc. from June 01, 2022 and serves as i...

Leadership Team

NamePositionTenureCompensationOwnership
Gilmore O’Neill
President2.6yrsUS$2.39m0.13%
$ 125.3k
Erick Lucera
CFO & Executive VP1.7yrsUS$2.69m0.028%
$ 26.3k
Linda Burkly
Executive VP & Chief Scientific Officer1.5yrsUS$1.73m0.018%
$ 16.5k
Baisong Mei
Executive VP & Chief Medical Officer2.5yrsUS$1.14m0.052%
$ 49.2k
Feng Zhang
Co-Founder & Scientific Advisory Board Member12yrsno datano data
George Church
Co-Founder & Scientific Advisory Board Member12yrsno datano data
Gregory Whitehead
Executive VP and Chief Technical & Quality Officerless than a yearno datano data
Cristi Barnett
Corporate Communications & Investor Relationsno datano datano data
Charlene Stern
Executive VP & General Counselno datano datano data
Linea Aspesi
Executive VP & Chief People Officer1.8yrsno datano data
Caren Deardorf
Executive VP and Chief Commercial & Strategy Officer1.3yrsno datano data

1.8yrs

Average Tenure

59yo

Average Age

Experienced Management: 0IFK's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Gilmore O’Neill
Presidentno dataUS$2.39m0.13%
$ 125.3k
Feng Zhang
Co-Founder & Scientific Advisory Board Memberno datano datano data
George Church
Co-Founder & Scientific Advisory Board Memberno datano datano data
Andrew Hirsch
Independent Director7.7yrsUS$210.56k0.0024%
$ 2.3k
Jessica Hopfield
Independent Chairman6.9yrsUS$231.07k0.082%
$ 77.2k
Elliott Levy
Independent Director1.8yrsUS$264.88k0%
$ 0
David Scadden
Independent Director5.9yrsUS$213.06k0%
$ 0
Bernadette Connaughton
Independent Director3.3yrsUS$215.06k0%
$ 0

5.9yrs

Average Tenure

66yo

Average Age

Experienced Board: 0IFK's board of directors are considered experienced (5.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/15 01:13
End of Day Share Price 2025/01/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Editas Medicine, Inc. is covered by 32 analysts. 15 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Joel BeattyBaird
Huidong WangBarclays